See more : US BioTec, Inc. (USBC) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (0HX7.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Teka Tecelagem Kuehnrich S.A. (TEKA3.SA) Income Statement Analysis – Financial Results
- Pine Cliff Energy Ltd. (PNE.TO) Income Statement Analysis – Financial Results
- Creades AB (CRED-A.ST) Income Statement Analysis – Financial Results
- ARGO Properties N.V. (ARGO.TA) Income Statement Analysis – Financial Results
- Pennsylvania Real Estate Investment Trust (PEI-PC) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (0HX7.L)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 0.00 | 0.00 |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 0.00 |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | -5.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 0.00% | 0.00% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 31.07M | 16.84M | 0.00 |
| General & Administrative | 26.53M | 26.30M | 22.22M | 15.66M | 8.69M | 8.43M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | -5.01M | -4.07M | -1.95M | -1.24M | 132.00K | 0.00 | 0.00 |
| SG&A | 26.53M | 21.29M | 18.15M | 13.71M | 7.45M | 8.56M | 2.04M | 1.00K |
| Other Expenses | 19.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 92.53M | 67.10M | 48.04M | 31.15M | 39.63M | 18.88M | 1.00K |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 49.99M | 32.38M | 39.71M | 18.88M | 1.00K |
| Interest Income | 9.98M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 |
| Interest Expense | 25.00K | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 0.00 |
| EBITDA | -136.54M | -64.70M | -57.88M | -37.41M | -30.15M | -37.51M | -18.88M | -1.00K |
| EBITDA Ratio | 0.00% | -270.28% | -589.58% | -168.35% | -3,030.15% | -484.35% | 0.00% | 0.00% |
| Operating Income | -152.04M | -72.55M | -61.43M | -32.09M | -31.39M | -39.71M | -18.88M | -1.00K |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -179.25% | -3,154.57% | -485.33% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 2.12M | -14.90M | 0.00 |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -37.59M | -33.78M | -1.00K |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -459.45% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | -125.00K | -2.82M | 19.00K | 26.00K | 0.00 | 0.00 |
| Net Income | -142.66M | -69.79M | -62.00M | -36.68M | -28.14M | -37.61M | -33.78M | -1.00K |
| Net Income Ratio | 0.00% | -279.27% | -637.19% | -204.87% | -2,827.94% | -459.77% | 0.00% | 0.00% |
| EPS | -3.31 | -1.70 | -2.00 | -5.01 | -13.15 | -9.96 | -58.97 | 0.00 |
| EPS Diluted | -3.31 | -1.70 | -2.00 | -5.01 | -13.15 | -9.96 | -58.97 | 0.00 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 2.14M | 3.78M | 572.79K | 4.01M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 2.14M | 3.78M | 572.79K | 4.01M |
Source: https://incomestatements.info
Category: Stock Reports